Adopted: 9/9/2020
Effective Date: 1/3/2021

VIRGINIA BOARD OF PHARMACY

Pharmacist Naloxone Statewide Protocol

Consistent with the naloxone manufacturer's instructions for use approved by the US Food and Drug Administration, a pharmacist may issue a prescription to initiate treatment with, dispense, or administer the following drugs and devices to persons 18 years of age or older:

- intranasal naloxone (nasal spray formulation or for administration by mucosal atomization device);
- intramuscular naloxone, including such controlled paraphernalia, as defined in § 54.1-3466, as may be necessary to administer such naloxone;
- naloxone auto-injector; or,
- any other opioid antagonist formulation approved by the FDA for overdose reversal, including such controlled paraphernalia, as defined in § 54.1-3466, as may be necessary to administer such naloxone.

PHARMACIST EDUCATION AND TRAINING

Prior to issuing a prescription to initiate treatment with, dispensing, or administering naloxone under this protocol, the pharmacist shall be knowledgable of the manufacturer's instructions for use, paraphernalia necessary for administration, and how to properly counsel the patient on recognizing signs of a possible overdose and proper administration of the drug.

PATIENT INCLUSION CRITERIA

Patients eligible for naloxone or other opioid antagonist approved by the FDA for overdose reversal under this protocol:

- An individual, 18 years of age or older, experiencing or at risk of experiencing an opioid-related overdose, e.g., patient has a history of prior overdose, substance misuse, a morphine milligram equivalency of 120MME/day, or is currently prescribed an opioid with a concomitant benzodiazepine present;
- A family member, friend, or other person, 18 years of age or older, in a position to assist an individual who is experiencing or at risk of experiencing an opioid-related overdose.

PATIENT EXCLUSION CRITERIA

Patients NOT eligible for naloxone or other opioid antagonist approved by the FDA for overdose reversal under this protocol:

- An individual less than 18 years of age;
- An individual receiving treatment of acute or chronic pain related to (i) cancer, (ii) sickle cell, (iii) a patient in hospice care, (iv) a patient in palliative care, (v) a patient enrolled in a clinical trial as authorized by state or federal law. Refer patient to primary care provider to determine if naloxone appropriate.

COUNSELING

The pharmacist shall ensure the patient or patient's agent is provided a copy of the REVIVE! Pharmacy dispensing brochure and ~~he or she shall~~ counsel the patient or the patient's agent on how

to properly identify signs of a possible overdose and how to properly administer the naloxone or other opioid antagonist for overdose reversal.

RECORDKEEPING
The pharmacist shall maintain records in accordance with Regulation 18VAC110-21-46.

NOTIFICATION OF PRIMARY CARE PROVIDER
In accordance with 54.1-3303.1 of the Code of Virginia, the pharmacist shall notify the patient's primary care provider. If the patient does not have a primary care provider, the pharmacist shall counsel the patient regarding the benefits of establishing a relationship with a primary health care provider and, upon request, provide information regarding primary health care providers, including federally qualified health centers, free clinics, or local health departments serving the area in which the patient is located.